Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$25.99 USD
+0.49 (1.92%)
Updated Apr 26, 2024 11:40 AM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Income Statements
Fiscal Year end for Pacira BioSciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 675 | 667 | 542 | 430 | 421 |
Cost Of Goods | 185 | 199 | 140 | 117 | 107 |
Gross Profit | 490 | 468 | 401 | 312 | 314 |
Selling & Adminstrative & Depr. & Amort Expenses | 403 | 408 | 311 | 266 | 304 |
Income After Depreciation & Amortization | 88 | 60 | 90 | 46 | 10 |
Non-Operating Income | -6 | -7 | -2 | -1 | 2 |
Interest Expense | 20 | 40 | 32 | 26 | 24 |
Pretax Income | 62 | 13 | 56 | 20 | -11 |
Income Taxes | 20 | -3 | 14 | -125 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 42 | 16 | 42 | 146 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 42 | 16 | 42 | 146 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 167 | 159 | 144 | 87 | 46 |
Depreciation & Amortization (Cash Flow) | 79 | 99 | 54 | 40 | 35 |
Income After Depreciation & Amortization | 88 | 60 | 90 | 46 | 10 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.98 | 46.54 | 45.63 | 43.68 | 41.51 |
Diluted EPS Before Non-Recurring Items | 2.09 | 1.84 | 2.26 | 1.30 | 0.86 |
Diluted Net EPS (GAAP) | 0.89 | 0.34 | 0.92 | 3.33 | -0.27 |
Fiscal Year end for Pacira BioSciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 181.24 | 163.93 | 169.47 | 160.34 |
Cost Of Goods | NA | 47.69 | 39.75 | 48.21 | 49.02 |
Gross Profit | NA | 133.55 | 124.18 | 121.26 | 111.32 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 100.38 | 106.45 | 81.38 | 114.41 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 33.17 | 17.73 | 39.88 | -3.09 |
Non-Operating Income | NA | 3.94 | 2.34 | 1.84 | -13.79 |
Interest Expense | NA | 3.39 | 3.46 | 3.87 | 9.59 |
Pretax Income | NA | 33.72 | 16.60 | 37.85 | -26.47 |
Income Taxes | NA | 8.85 | 5.74 | 12.09 | -6.94 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 24.87 | 10.86 | 25.76 | -19.54 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 24.87 | 10.86 | 25.76 | -19.54 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 52.06 | 52.07 | 52.05 | 45.95 |
Diluted EPS Before Non-Recurring Items | NA | 0.71 | 0.52 | 0.61 | 0.32 |
Diluted Net EPS (GAAP) | NA | 0.58 | 0.23 | 0.51 | -0.43 |